C1-Inh administration in different clinical conditions
| Clinical condition | Number of patients | Dosage of C1-Inh | Results | References |
|---|---|---|---|---|
| Septic shock | 5 | 2000 U i.v. bolus followed by 1000 U daily for 4 days | No side effects, less vasopressor medication, no death | Hack et al., 1992 |
| Septic shock | 6 | 4000 U i.v. bolus, followed by 2000, 2000, and 1000 U or 6000 U i.v. bolus, followed by 3000, 2000, and 1000 U every 12 h | No side effects, no death | Hack et al., 1993 |
| Open heart surgery; emergency coronary artery bypass grafting after failed percutaneous transluminal coronary angioplasty | 3 | 2000 U i.v. bolus, followed by 1000 U after 12 and 24 h, respectively | Hemodynamic stabilization, improved myocardial contractility | Bauernschmitt et al., 1998 |
| Vascular leak syndrome following bone marrow transplantation | 15 | 60 U/kg i.v. bolus, followed by 2 × 30 U/kg and 4 × 15 U/kg every 12 h | 1 year survival, 57% vs. 14% of controls | Nürnberger et al., 1997 |
| Vascular leak syndrome following high dose therapy with IL-2 in cancer patients | 6 (with metastatic melanoma or renal cell carcinoma) | 2000 U bolus i.v. followed by 1000 U every 12 h for 4 days | Comparable side effects of IL-2 despite 4-fold higher doses during treatment | Ogilvie et al., 1994 |
| Vascular leak syndrome following open heart surgery | 29 (children) | 300 U/kg bolus i.v. followed by 2 doses of 150 U/kg, 3 doses of 100 U/kg, and 3 doses of 50 U/kg every 8 h | Improved hemodynamic, respiratory, and laboratory parameters, persistent vascular leak syndrome in 3 children, no amelioration of diuresis in 6 children | Stieh et al., 1996 |
| Severe thermal injury with septic shock | 16 (with severe burns and shock, systemic inflammatory response syndrome, or septic shock) | 6000 U i.v. bolus, followed by 3000, 2000, and 1000 U every 12 h | Trend to reduced mortality (50 vs. 26% in a control group) | Jostkleigreve et al., 1997 |